[
Armstrong, A., Jarvis S., Boehncke, W. H., Rajagopalan, M. (2018). Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis, results of the Clear About Psoriasis worldwide survey. J. Eur. Acad., Dermatol. Venereol., 32, 2200–2207.10.1111/jdv.1506529730888
]Search in Google Scholar
[
Bongiorno, M. R., Pistone, G., Doukaki, S., Arico, M. (2008). Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis. Dermatol. Ther., 21, 15–20.10.1111/j.1529-8019.2008.00227.x18837728
]Search in Google Scholar
[
Caiazzo, G., Fabbrocini, G., Di Caprio, R. (2018). Psoriasis, cardiovascular events, and biologics, lights and shadows. Front Immunol., 9, 1–12.10.3389/fimmu.2018.01668609915930150978
]Search in Google Scholar
[
Chiricozzi, A., Romanelli, P., Volpe, E., Borsellino, G., Romanelli, M. (2018). Scanning the immunopathogenesis of psoriasis. Int. J. Mol. Sci., 19 (179), 1–31.10.3390/ijms19010179579612829316717
]Search in Google Scholar
[
Chiricozzi, A., Zangrilli, A., Bavetta, M., Bianchi L. (2017). Real-life 9-year expierence with adalimumab in psoriasis and psoriatic arthritis, results of a single-centre, retrospective study. J. Eur. Acad., Dermatol. Venereol., 31, 304–311.10.1111/jdv.1377127324646
]Search in Google Scholar
[
Constantin, M. M., Poenaru E., Constantin, T., Poenaru, C., Purcarea, V. L., Mateescu, B. R. (2014). Biological therapies in moderate and severe psoriasis, perspectives and certainties. J. Med. Life, 7, 15–17.
]Search in Google Scholar
[
Elyoussfi, S., Thomas, B. J., Ciurtin, C. (2016). Tailored treatment options for patients with psoriatic arthritis and psoriasis, review of established and new biologic and small molecile therapies. Rheumatol. Int., 36, 603–612.10.1007/s00296-016-3436-0483904626892034
]Search in Google Scholar
[
Gisondi, P., Cazzaniga, S., Chimenti. S. (2013a). Metabolic abnormalities associated with initation of systemic treatment for psoriasis, evidence from the Italian Psocare Registry. J. Eur. Acad., Dermatol. Venereol., 27, 30–41.10.1111/j.1468-3083.2012.04450.x22313340
]Search in Google Scholar
[
Gisondi, P., Tessari, G., Di Mercurio, M., Del Giglio, M, Girolomoni G. (2013b). The retention rate of systemic drugs in patients with chronic plaque psoriasis. Clin. Dermatol., 1, 8–14.
]Search in Google Scholar
[
Gniadecki, R., Leonardi, C. L, Gordon, K. B., Gu, Y. (2018). Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis. J. Eur. Acad., Dermatol. Venereol., 32, 1297–1304.10.1111/jdv.1492629524255
]Search in Google Scholar
[
Gonzalez, J. M., Johnson F. R., McAteer, H., Posner, J., Mughal, F. (2017). Comparing preferences for outcomes of psoriasis treatments among patients and dermatologists in the U.K., results from a discrete- choice experiment. Brit. J. Dermatol., 176, 777–785.10.1111/bjd.1479827292093
]Search in Google Scholar
[
Hartmane I., Mikažāns I., Ivdra, I. (2016). Vidēji smagas un smagas gaitas psoriāzes klīniskās vadlīnijas [Clinical guidelines for moderate to severe psoriasis]. Rīga Stradiņš University. www.vmnvd.gov.lv (accessed 15.09.2021) (in Latvian).
]Search in Google Scholar
[
Jackson, J. M. (2007). TNF-α inhibitors. Dermatol. Ther., 20, 251–264.10.1111/j.1529-8019.2007.00138.x17970890
]Search in Google Scholar
[
Jacobi, A, Mahler, V., Schuler, G., Heri, M. (2006). Treatment of inflammatory dermatosi by tumor necrosis factor antagonists. J. Eur. Acad., Dermatol. Venereol., 20, 1171–1187.10.1111/j.1468-3083.2006.01733.x17062028
]Search in Google Scholar
[
Krueger, J. G. (2002). The immunologic basis for the treatment of psoriasis with new biologic agents. J. Amer. Acad. Dermatol., 46, 1–23.10.1067/mjd.2002.12056811756941
]Search in Google Scholar
[
Langewouters, A. M. G., van Erp, P. E. J., de Jong, E. M. G. J., van de Kerkhof, P. C. M. (2007). Lymphocyte subsets in peripheral blood of patients with moderate-to-severe versus mild plaque psoriasis. Arch. Dermatol. Res., 300, 107–113.10.1007/s00403-007-0819-9225465818157542
]Search in Google Scholar
[
Laurent, M. R., Panay, G., Shepherd, P. (1981). Circulating immune complexes, serum immunoglobulins, and acute phase proteīns in psoriasis and psoriatic arthritis. Ann. Rheum. Dis., 40, 66–69.10.1136/ard.40.1.6610006596970552
]Search in Google Scholar
[
Leonardi, C., Papp, K., Strober, B., Thaci, D., Warren, R. B. (2019). Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis. Brit. J. Dermatol., 180, 76–85.10.1111/bjd.1708430169904
]Search in Google Scholar
[
Loos, A. M., Liu, A., Segel, C., Ollendorf, D. A. (2018). Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis, a systematic review and network meta-analysis. J. Amer. Acad. Dermatol., 79, 135–144.10.1016/j.jaad.2018.02.02729438757
]Search in Google Scholar
[
Mahil, S. K., Capon, F., Barker, J. N. (2016). Update on psoriasis immuno-pathogenesis and targeted immunotherapy. Semin. Immunopathol., 38, 11–27.10.1007/s00281-015-0539-8470657926573299
]Search in Google Scholar
[
Menter, A., Thaci, D., Papp, K., Wu, J. J., Bereswill, M. (2015). Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. J. Amer. Acad. Dermatol., 73, 410–419.10.1016/j.jaad.2015.06.03826190240
]Search in Google Scholar
[
Nacionālais Veselības Dienests. Kompnsējamo zāļu saraksts [National Health Service. Reimbursement drug list]. http://www.vmnvd.gov.lv/lv/kompensejamie-medikamenti/kompensejamo-zalu-saraksts from 06/04/2020 (accessed 15 April 2020) (in Latvian).
]Search in Google Scholar
[
Nast, A., Boehncke, W. H., Mrowietz, U. (2012). S3-guidelines on the systemic treatment of psoriasis vulgaris. J. Dtsch. Dermatol. Ges., 10 (2), 1–95.
]Search in Google Scholar
[
Nast, A., Gisondi, P., Ormerod, A. D., Saiag, P., Smith, C., Puls, P. I., Arenberger, P., Barker, J., Dauden, E., de Jong, E. M. et al. (2015). European S3-guidelines on the systemic treatment of psoriasis vulgaris — Update 2015 — Short version — EDF in cooperation with EADV and IPC. J. Eur. Acad., Dermatol. Venereol., 29, 2277–2294.10.1111/jdv.1335426481193
]Search in Google Scholar
[
Oztürk, G., Erbaŗ D., Gelir, E., Gülekon, A., Imir, T. (2001). Natural killer cell activity, serum immunoglobulins, complement proteins, and zinc levels in patients with psoriasis vulgaris. Immunol. Invest., 30, 181–190.10.1081/IMM-100105063
]Search in Google Scholar
[
Papp, K., Crowley J., Ortonne, J. P. (2011). Adalimumab for moderate to severe chronic plaque psoriasis, efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Brit. J. Dermatol., 164, 434–441.10.1111/j.1365-2133.2010.10139.x21083543
]Search in Google Scholar
[
Papp, K., Menter, A., Poulin Y., Gu, Y., Sasso, E. H. (2013). Long-term outcomes of interrruption and retrearment vs. continuous therapy with adalimumab for psoriasis, subanalysis of REVEAL and the open-label extension study. J. Eur. Acad., Dermatol. Venereol., 27, 634–642.10.1111/j.1468-3083.2012.04515.x22429586
]Search in Google Scholar
[
Patel, T., Gordon, K. B. (2004). Adalimumab, efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol. Ther., 17, 427–431.10.1111/j.1396-0296.2004.04045.x15379777
]Search in Google Scholar
[
Poulin, Y., Crowley, J. J., Langley, R. G. (2014). Effeicacy of adalimumab across subgoups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet, post hoc analysis of REACH. J. Eur. Acad., Dermatol. Venereol., 28, 882–890.10.1111/jdv.12198422902523790018
]Search in Google Scholar
[
Puig, L., Thorm, H., Mollon, P., Thian, H., Ramakrishina, G. S. (2017). Clear or almost ckear skin improves the quality of life in patients with moderate-ro-severe psoriasis, a systematic review and meta-analysis. J. Eur. Acad., Dermatol. Venereol., 31, 213–220.10.1111/jdv.1400727739123
]Search in Google Scholar
[
Rendon, A., Schake, K. (2019). Psoriasis pathogenesis and treatment. Int. J. Mol. Sci., 20, 1–28.10.3390/ijms20061475647162830909615
]Search in Google Scholar
[
Ronholt, K., Iversen, L. (2017). Old ans new biological therapies for psoriasis. Int. J. Mol. Sci., 18, 1–28.10.3390/ijms18112297571326729104241
]Search in Google Scholar
[
Sawyer, L. M., Cornic, L, Levin, L. A., Gibbons, C. (2019). Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis, a systematic review and network meta-analysis of PASI response. J. Eur. Acad., Dermatol. Venereol., 33, 355–366.10.1111/jdv.15277658778030289198
]Search in Google Scholar
[
Strober, B., Crowley, J., Langley, R. G., Gordon K. (2018). Systematic review of the real-world evidence of adalimumab safety in psoriasis registries. J. Eur. Acad., Dermatol. Venereol., 32, 2126–2133.10.1111/jdv.1520330067882
]Search in Google Scholar
[
Strober, B. E., Poulin, Y., Kerdel, F. A., Langley, R. G. (2010). Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy, efficacy and safety results from an open-label study. J. Amer. Acad. Dermatol., 64, 671–679.10.1016/j.jaad.2010.03.00921414495
]Search in Google Scholar
[
Takeshita, J., Grewal, S., Langan, S. M., Mehta, N. N. (2017). Psoriasis and comorbid diseases. J. Amer. Acad. Dermatol., 76, 377–390.10.1016/j.jaad.2016.07.064573165028212759
]Search in Google Scholar
[
Talamonti, M., Galluzo, M., Bernardini, N., Caldarola, G. (2018). Psoriasis area and severity index response in moderate-severe psoriatic patients switched to adalimumab, results from the OPPSA study. J. Amer. Acad. Dermatol., 32, 1737–1744.10.1111/jdv.1507729776016
]Search in Google Scholar
[
Thomas, J., Kupper, M., Batra, R., Jargosch, M., Atenhan, A. (2019). Is the humoral immunity dispensable for the pathogenesis of psoriasis? J. Amer. Acad. Dermatol., 33, 115–122.10.1111/jdv.1510129856508
]Search in Google Scholar
[
Toruniowa, B. (1992). Humoral indices of the inflammatory process in psoriasis. Pol. Tyg. Lek., 2, 44–45.
]Search in Google Scholar
[
Vaidya, T., Feldman, S. R., Kirk, J. (2015). Patient-centered approach to biologics in the treatment of psoriasis. J. Nat. Sci., 1, 1–7.
]Search in Google Scholar
[
Van Luming, P. P. M., Driessen, R. J. B., Roelofs-Thijssen, M. A. M. A. (2011). Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumab. Brit. J. Dermatol., 165, 375–382.10.1111/j.1365-2133.2011.10329.x21428975
]Search in Google Scholar
[
Van Luming, P. P. M., Lecluse, L. L. A., Driessen, R. J. B. (2010). Switching from etanercept to adalimumab is effective and safe, results in 30 patients with psoriasis primary failure, secondary failure or intolerance3 to etenercept. Brit. J. Dermatol., 163, 838–846.10.1111/j.1365-2133.2010.09950.x20649798
]Search in Google Scholar
[
Winterfield, L. S., Menter, A. (2004). Infliximab. Dermatol. Ther., 17, 409–426.10.1111/j.1396-0296.2004.04044.x15379776
]Search in Google Scholar
[
Wy, J. J., Joshi, A. A., Reddy, S. P., Batech, M. (2018). Anti-inflammatory therapy with tumor necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis. J. Eur. Acad., Dermatol. Venereol., 32, 1320–1326.10.1111/jdv.1495129573294
]Search in Google Scholar
[
Zweegers, J., Otero, M. E. (2016). Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practoce, a systematic review. Acta Derm. Venerol., 96, 453–458.10.2340/00015555-227626537336
]Search in Google Scholar
